Mounjaro®
Starting from £179.99/mo
Start journey Learn moreReaching your goal weight on Wegovy is a real clinical milestone — and it raises an immediate practical question that many people haven't thought about yet. When you reach goal weight on Wegovy, treatment doesn't simply end. The evidence shows that semaglutide works by continuously suppressing appetite through GLP-1 receptor activity, and that effect stops when the medicine does. For most people, this means goal weight is not the finish line so much as the point where the next conversation with your prescriber becomes urgent. Wegovy is a prescription-only medicine, so what happens next is a clinical decision, not one to make alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Think of it this way: the medicine has done the appetite-suppression work, but the biology that made weight gain likely in the first place hasn't changed. GLP-1 receptor agonists like semaglutide address the hormonal signalling around hunger and satiety while you're taking them. That's not a criticism of the medicine, it's how it works, and it works well. The STEP 1 trial, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. What that trial also confirmed, in its withdrawal extension, was that most of that weight returned once semaglutide was stopped.
So when you reach goal weight, you're not choosing between "stay on Wegovy" and "come off Wegovy and everything is fine". You're choosing between a set of genuinely different paths, each with trade-offs. Understanding those trade-offs is what the conversation with your prescriber is for. How Wegovy works throughout treatment can help set that context before you get there.
Staying on Wegovy at a lower or maintenance dose while consolidating lifestyle habits is one option your prescriber may discuss. There's a reasonable rationale: the medicine keeps appetite suppression in place while you build sustainable eating and activity patterns. The practical complication is the NICE recommendation. NICE's appraisal of semaglutide for weight management (TA875) recommends use for a maximum of two years within a specialist weight management service, so open-ended continuation isn't the standard NHS pathway, though private prescribing follows clinical judgement alongside the licensed use.
Private treatment through a regulated pharmacy like ours means your prescriber reviews your situation before every repeat order, every time, not just at the two-year mark. If you're approaching goal weight and wondering about cost over a longer maintenance period, our Wegovy cost page lays out what's included in private treatment pricing.
One thing worth saying plainly: if you order by 12pm on a weekday (say, the Monday after payday, which is when a lot of repeat requests come through) dispatch happens the same day once clinical review is complete. The timing matters because a break in treatment, even a short one, can affect how quickly your appetite shifts.
This is the part that catches people off guard. If you want to understand what happens when you stop taking Wegovy, the short answer is that most clinical evidence (including data from the semaglutide withdrawal studies) shows appetite returning significantly within weeks, with weight regain following over the subsequent months. That's not failure; it's the predictable consequence of removing a medicine that was actively doing a hormonal job.
The distinction that matters at goal weight is between stopping abruptly, tapering gradually under prescriber guidance, or transitioning to a different strategy. None of these are decisions to take based on the fact that the scales have reached a number. A prescriber needs to know your weight trajectory over time, your current dose, and what lifestyle habits are genuinely in place. The full picture of what stopping means for weight loss specifically covers this in more detail.
If you've been considering other weight-loss treatment options, goal weight is also a natural point to ask your prescriber whether any adjustment to your approach makes sense.
The most useful thing you can do before reaching goal weight is raise the question early, not the day the scales hit the target. A question our prescribers hear regularly in aftercare check-ins is: "When do I stop, and what happens next?" The honest answer is that it varies by person, and any prescriber giving a one-size answer isn't giving a clinical one.
What a prescriber will want to consider: how long you've been at the maintenance dose, whether the weight loss has plateaued or is still gradual, what weight-related health conditions you started with and where they now stand, and whether you have a realistic picture of your eating and activity post-treatment. Getting off Wegovy safely and with the least risk of rebound is a process, not an event. The general FAQs cover common questions about Wegovy treatment if you want background before your review.
Pregnancy, breastfeeding, and trying to conceive are all reasons why a prescriber would recommend stopping semaglutide; the same applies to any significant change in health status. These are clinical decisions the prescriber makes with you, not administrative ones.
If you're reaching goal weight and want a clinical review of your next steps, our prescribers are available seven days a week. Speak to our prescribers through a free consultation to talk through what makes sense for your situation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.